Press Room


    Press Release - January 19, 2012

    Sernova Receives Patent Allowance in Japan

    January 19, 2012, 6:00 a.m. EST

    LONDON, ONTARIO--(Marketwire -- Jan. 19, 2012) - Sernova Corp. (TSX-V: SVA), today announced that the Japan Patent Office has issued a Notice of Allowance to Sernova for a patent entitled "Compositions Containing Sertoli Cells and Myoid Cells and Use Thereof in Cellular Transplants." Allowance in additional international jurisdictions including Canada, Europe, and the United States is pending while allowance in Australia has been granted.

    "This patent allowance further strengthens our patent portfolio of over 22 issued and pending patents covering our enabling platforms of therapeutic cells, local immunoprotection and medical devices, including the Cell Pouch System(TM)," said Dr. Philip Toleikis, Sernova's President and CEO. "The claims in this patent position Sernova to expand its platform to a wide range of therapeutic cell types, which are important in treating chronic diseases, and enable us to further establish partnering and development opportunities as we continue to advance our Cell Pouch System(TM). Our upcoming evaluation of the Cell Pouch(TM) in patients with diabetes is part of this important process."

    Sernova has presented compelling evidence at leading scientific conferences demonstrating that the Cell Pouch System(TM) can be used as a safe and effective platform for delivery of insulin from both autograft (self) and allograft (donor) islets to restore glucose control in stringent preclinical models of diabetes using the human scaled product. Sernova is currently preparing for safety and efficacy evaluation of the Cell Pouch System (TM) in humans in the first study of its kind in the world.

    In the future, Sernova plans to explore the additional utility of the Cell Pouch System(TM) as an enabling platform for a range of therapeutic cell types with the potential to treat multiple chronic debilitating diseases where there are broad unmet medical needs.

    About Sernova

    Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

    For further information contact:

    Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

    Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required

Latest Video and Presentation

Sernova Fact Sheet - / September 11, 2017 Open

Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →